ReviewNature reviews. Disease primers2021
Hepatocellular carcinoma.
Review in Nature reviews. Disease primers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 10 registered trials, which are not on this map. Cited by 4,184 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.
The Prognostic Value of Circulating Tumor Cells Isolated by a Novel Microfluidic Platform in Liver Cancer Patients
Assessing the Prognosis of Transarterial Chemoembolization in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies(VEGF-TKI/Bevacizumab) for Hepatocellular Carcinoma by Using Clinical and Imaging Biomarkers
Efficacy and Safety of Transarterial Chemoembolization in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies(VEGF-TKI/Bevacizumab) for Intermediate Stage HCC
Efficacy and Safety of Transarterial Chemoembolization in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies(VEGF-TKI/Bevacizumab) for Advanced Stage HCC
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
Hepatocellular Carcinoma Organoids to Explore Tumor Microenvironment and Test Treatment Efficacy - Hepatocellular Carcinoma Liver Organoids (HELIO)
Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)
A Phase 2, Multicenter, Randomized, Open-label Study Comparing Fostrox + Lenvatinib vs. Lenvatinib in Patients With Locally Advanced or Unresectable Advanced Hepatocellular Carcinoma (HCC) Who Have Received First-line Combination Immunotherapy
A Multicenter, Phase II Study to Evaluate the Safety and Efficacy of Atezolizumab, Bevacizumab, and Tocilizumab in Patients With Advanced Hepatocellular Carcinoma
Who cites it
4,184 citing papers in PubMed, 3 syntheses or guidelines pooled it, 6,195 citations in OpenAlex.
- Efficacy and safety of terlipressin infusion during liver surgery: a meta-analysis.Updates in surgery · 2026Pooled it
- Pathological and Perioperative Outcomes of Conversion Hepatectomy After Contemporary Combination Downstaging for Initially Unresectable Hepatocellular Carcinoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- Diagnostic accuracy of circulating long noncoding RNAs in hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Quantitative Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Radioembolization.Investigative radiology · 2026Trial
- Different regulatory mechanisms of hepatitis B- and C-positive hepatocellular carcinoma by single-cell RNA sequencing.Genes & diseases · 2027Article
- Stress-specific 14-3-3-client modules in digestive cancers: an evidence-graded review of adaptive survival and therapy resistance.Cancer biology & therapy · 2026Review
- Oncolytic virus therapy for hepatocellular carcinoma: A bibliometric analysis of research landscapes, hotspots, and clinical transformation trends from 2000 to mid-2025.Human vaccines & immunotherapeutics · 2026Review
- A Self-assembly Carrier-Free Nanovaccine based on Fluorinated CpG and Neoantigen Peptides for Hepatocellular Carcinoma Immunotherapy.International journal of pharmaceutics: X · 2026Article
- Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.Hepatic oncology · 2026Review
- Ginkgolic acid targets HSPA8 to trigger ferroptosis in hepatocellular carcinomaPharmaceutical biology · 2026Article
- RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells.Hepatic oncology · 2026Article
- Characteristics of hepatocellular carcinoma in a Saudi tertiary care center: a 10-year retrospective study.Hepatic oncology · 2026Article
- Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice.The Lancet regional health. Europe · 2026Review
- AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma.British journal of cancer · 2026Article
- Hemorrhagic hepatocellular carcinoma managed with urgent transarterial particle embolization: A case report.Radiology case reports · 2026Article
- VMAT-based lattice radiotherapy for advanced bulky hepatocellular carcinoma within multimodality treatment: a consecutive feasibility series.Clinical and translational radiation oncology · 2026Article
- Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis.Abdominal radiology (New York) · 2026Review
- Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2026Article
- Glass versus resin microspheres in ⁹⁰Y radioembolization for hepatocellular carcinoma: toxicity patterns under uniform voxel-based dosimetry.Annals of nuclear medicine · 2026Article
4,124 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 10 institutions in 6 countries.
Funding
Abstract
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis associated with metabolic syndrome or diabetes mellitus is becoming a more frequent risk factor in the West. Moreover, non-alcoholic steatohepatitis-associated HCC has a unique molecular pathogenesis. Approximately 25% of all HCCs present with potentially actionable mutations, which are yet to be translated into the clinical practice. Diagnosis based upon non-invasive criteria is currently challenged by the need for molecular information that requires tissue or liquid biopsies. The current major advancements have impacted the management of patients with advanced HCC. Six systemic therapies have been approved based on phase III trials (atezolizumab plus bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab) and three additional therapies have obtained accelerated FDA approval owing to evidence of efficacy. New trials are exploring combination therapies, including checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies, or even combinations of two immunotherapy regimens. The outcomes of these trials are expected to change the landscape of HCC management at all evolutionary stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.